EUCTR2007-001857-24-GB进行中（未招募）1 期
A Phase IIa, open-label, dose-titration, multicentre study to assess the safety and preliminary efficacy of NI-0401 in patients with acute cellular renal allograftt rejection
ovImmune S.A.0 个研究点目标入组 12 人开始时间: 2007年7月31日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •1.Men and women = 18 and = 70 years of age.
- •2.Recipient of a kidney graft (first or second) from a deceased or living donor (non-HLA-identical).
- •3.Rise in SCr concentration by > 20% compared to baseline, defined as the most recent creatinine level measured prior to rejection but after transplantation.
- •4.Allograft biopsy showing evidence of acute cellular rejection, according to Banff 97 criteria.
- •5.Men and women of childbearing potential must use adequate birth control measures until 6 months after receiving study drug. Therefore, women of childbearing potential and their partners are required to use two forms of contraception. Men with partners of childbearing potential are required to use barrier contraception, in addition to their partners using another method. Acceptable forms of contraception are as follows:
- •-Barrier methods: condoms, diaphragms, cervical caps;
- •-Hormonal contraceptives: combination or progesterone only;
- •Includes depot contraceptives;
- •-Intrauterine methods: intrauterine devices or systems.
- •6.The screening laboratory tests must meet the following criteria:
- •a.Hb ³ 8.5 g/dL (4.5 mmol/L)
- •b.WBC ³ 4 x 109/L
- •c.Neutrophils ³ 1.5 x 109/L
- •d.Platelets ³ 100 x 109/L
- •e.The hepatic function tests (including transaminases and alkaline phosphatase) are in the normal ranges for the patient as evaluated by investigator..
- •7.Patients must be able to adhere to the study visits and protocol requirements.
- •8.Patients must be able to give written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Patients who have received therapy for the current graft with anti-CD3 mAb (OKT3) or anti-lymphocytes polyclonal antibodies (ATG, Atgam) in the past.
- •2.Patients with cardiac insufficiency or fluid overload (to be excluded by a chest X ray).
- •3.Severe HLA sensitization (>50% panel reactive antibodies prior to transplantation).
- •4.Evidence of delayed renal graft function.
- •5.Have received or are planned to receive immunization with a live vaccine within 6 weeks prior to receiving study drug and 12 weeks after treatment cessation.
- •6.Concomitant disease:
- •a.Current signs or symptoms of severe, progressive or uncontrolled disease. Patients with cardiac (e.g. recent myocardial infarction or symptomatic ischemic heart disease); pulmonary (e.g. chronic obstructive pulmonary disease); or neurologic disease (e.g. seizure disorder or head trauma).
- •b.Previous diagnosis of, or known, malignancies, except for completely excised basal cell carcinoma.
- •c.Ongoing severe infections, such as hepatitis or pneumonia, or any active infection (requiring therapy).
- •d.History of opportunistic infections such as herpes zoster within 2 months prior to screening. History of active tuberculosis (TB) or currently undergoing treatment for TB.
- •e.Evidence of acute CMV (or D+/R-) or EBV infection.
- •f.Serum anti HCV positive, serum HBsAg positive, serum anti-HIV positive.
- •g.Patients with BK Virus nephropathy.
- •7.Patients with any history of coagulopathy or medical condition requiring long-term anticoagulation after transplantation (low-dose of aspirin treatment is allowed).
- •8.Female patients who are pregnant or breast feeding.
- •9.A psychiatric, addictive, or any other disorder that compromises the ability to give truly informed written consent for participation in this study.
- •10.Suspected hypersensitivity to any component of the drug product.
- •11.Has undergone or is undergoing treatment with another investigational drug or approved therapy for investigational use within 3 months prior to entry in this study. Has previously participated in this study.
- •12. Patients for whom pre-study assessment would lead to delay (as judged by the investigator) in initiating therapy with NI-0401.
研究者
相似试验
进行中（未招募）
1 期
A Phase IIa, open-label, dose-titration, multicentre study to assess the safety and preliminary efficacy of NI-0401 in patients with acute cellular renal allograftt rejectioEUCTR2007-001857-24-FRovImmune S.A.12
进行中（未招募）
1 期
A Phase IIa, open-label, dose-titration, multicenter study to assess the safety and preliminary efficacy of NI-0401 in patients with acute cellular renal allograftt rejectioAcute cellular renal allograft rejection.EUCTR2007-001857-24-PLovImmune S.A.12
进行中（未招募）
1 期
A Trial of Lu AG13909 in Adult Participants with Cushing’s DiseaseCushing's DiseaseMedDRA version: 20.0Level: LLTClassification code: 10011651Term: Cushing's disease Class: 10014698CTIS2023-504733-53-00H. Lundbeck A/S18
进行中（未招募）
1 期
A study to evaluate the safety, tolerability, processing by the body, mechanism of action, and effectiveness of glofitamab following obinutuzumab pretreatment in patients with B-cell non-Hodgkin lymphomaB-cell non-Hodgkin lymphomaB-cell lymphoma, unspecifiedCancerISRCTN17975931Genentech, Inc36
进行中（未招募）
不适用
A Phase Ib/II study of LGX818 in combination with MEK162 in adult patients with BRAF dependent advanced solid tumorsEUCTR2011-005875-17-FRovartis Pharma Services AG127